Abstract
Comprehensive molecular testing is essential to provide personalized and effective care for patients with metastatic non-squamous (non-Sq) NSCLC. Ordering of next-generation gene sequencing (NGS) is often delayed until the first medical oncology visit. To improve rates of timely comprehensive molecular profiling among newly diagnosed patients with advanced non-Sq NSCLC, we implemented a reflex, molecular testing pathway (NGS and RNA fusion panel) on tumor, nodal or metastatic specimens, initiated at the time of initial pathology review, that obviated the need for a separate specimen-specific order.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
